Named Lecture:
208. Joseph E. Smadel Lecture: The Evolution of Antiretroviral Agents
Saturday, October 5, 2013: 3:45 PM-4:30 PM
Room: The Moscone Center: Esplanade Ballroom 301-310
Co-organized with the Center for Global Health Policy

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • discuss the remarkable development of a myriad of agents that allow normal life span in people with HIV infection--literally changing the prognosis from certain death to survival
  • describe the use of some of these agents--based on pharmacological properties--for concomitant prevention of transmission, and implementation of this approach
  • discuss the race to cure HIV, including implications of early treatment, development of new agents,  and pharmaco-immunology as the way forward

Target Audience: vaccinologists, scientists, researchers, public health practitioners, pharmacists, nurses, microbiologists, members-in-training, lab personnel, investigators, infectious diseases physicians, infectious diseases pediatricians, infection preventionists, hospital epidemiologists, hospital administrators, HIV specialists, HIV clinicians, health care workers, fellows, epidemiologists, clinicians, academicians

Tracks: Pediatric ID, Investigative ID, HIV-STD-TB, Global ID, Epidemiology and Infection Control, Adult ID

Moderator:  Joel Gallant, MD, MPH, FIDSA, Southwest Care Center

CME Credits:

ACPE Credits: ACPE 0.75 knowledge-based contact hours (0.075 CEU) of pharmacy CE

ACPE Number: 0221-9999-13-128-L02-P

Disclosures:

J. Gallant, Gilead Sciences: Investigator and Scientific Advisor, Consulting fee and Research grant
Bristol-Myers Squibb: Scientific Advisor, Consulting fee
Merck & Co.: Scientific Advisor, Consulting fee
Janssen Therapeutics: Scientific Advisor, Consulting fee
Takara Bio, Inc.: Scientific Advisor, Consulting fee

M. Cohen, None

See more of: Named Lecture

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.